|
1
|
Lee JM, Tsuboi M and Brunelli A: Surgical
perspective on neoadjuvant immunotherapy in non-small cell lung
cancer. Ann Thorac Surg. 114:1505–1515. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kang J, Zhang C and Zhong WZ: Neoadjuvant
immunotherapy for non-small cell lung cancer: State of the art.
Cancer Commun (Lond). 41:287–302. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jia XH, Xu H, Geng LY, Jiao M, Wang WJ,
Jiang LL and Guo H: Efficacy and safety of neoadjuvant
immunotherapy in resectable nonsmall cell lung cancer: A
meta-analysis. Lung Cancer. 147:143–153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng H, Liu J, Cai X, Chen J, Rocco G,
Petersen RH, Brunelli A, Ng CSH, D'Amico TA, Liang W and He J:
Radical minimally invasive surgery after immuno-chemotherapy in
initially-unresectable stage IIIB non-small cell lung cancer. Ann
Surg. 275:e600–e602. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong P, Yan Y, Yang L, Wu D, Wang H, Lv Y,
Zhang J and Yu X: Neoadjuvant immunotherapy improves treatment for
early resectable non-small-cell lung cancer: A systematic review
and meta-analysis. J Oncol. 2022:20852672022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalvapudi S, Vedire Y, Yendamuri S and
Barbi J: Neoadjuvant therapy in non-small cell lung cancer: Basis,
promise, and challenges. Front Oncol. 13:12861042023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen LN, Wei AZ and Shu CA: Neoadjuvant
immunotherapy in resectable non-small-cell lung cancer. Ther Adv
Med Oncol. 15:175883592311637982023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Riely GJ, Wood DE, Ettinger DS, Aisner DL,
Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, et
al: Non-small cell lung cancer, version 4.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
22:249–274. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deutsch JS, Cimino-Mathews A, Thompson E,
Provencio M, Forde PM, Spicer J, Girard N, Wang D, Anders RA,
Gabrielson E, et al: Association between pathologic response and
survival after neoadjuvant therapy in lung cancer. Nat Med.
30:218–228. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Verma S, Breadner D, Mittal A, Palma DA,
Nayak R, Raphael J and Vincent M: An updated review of management
of resectable stage III NSCLC in the era of neoadjuvant
immunotherapy. Cancers (Basel). 16:13022024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matilla JM, Zabaleta M, Martínez-Téllez E,
Abal J, Rodríguez-Fuster A and Hernández-Hernández J: New TNM
staging in lung cancer (8th edition) and future perspectives. J
Clin Transl Res. 6:145–154. 2020.PubMed/NCBI
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sorin M, Prosty C, Ghaleb L, Nie K,
Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, et
al: Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review
and meta-analysis. JAMA Oncol. 10:621–633. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aguado C, Chara L, Antoñanzas M, Matilla
Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes
JC and Couñago F: Neoadjuvant treatment in non-small cell lung
cancer: New perspectives with the incorporation of immunotherapy.
World J Clin Oncol. 13:314–322. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferrari V and Helissey C: Revolutionizing
localized lung cancer treatment: Neoadjuvant chemotherapy plus
immunotherapy for all? J Clin Med. 13:27152024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bunn PA Jr, Mault J and Kelly K: Adjuvant
and neoadjuvant chemotherapy for non-small cell lung cancer: A time
for reassessment? Chest. 117 (4 Suppl 1):119S–122S. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aguado C, Jiménez Maestre UJ and
Mielgo-Rubio X: Neoadjuvant immunotherapy in non-small-cell lung
cancer: Times are changing-and fast. World J Clin Oncol.
13:758–761. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guven DC, Sahin TK and Kilickap S: The
efficacy and safety of neoadjuvant immunotherapy in patients with
non-small cell lung cancer. Cancers (Basel). 16:1562023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Provencio M, Nadal E, González-Larriba JL,
Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo
V, Insa A, Ponce S, et al: Perioperative nivolumab and chemotherapy
in stage III non-small-cell lung cancer. N Engl J Med. 389:504–513.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Provencio M, Nadal E, Insa A, García
Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu
D, Martínez-Martí A, et al: Perioperative chemotherapy and
nivolumab in non-small-cell lung cancer (NADIM): 5-Year clinical
outcomes from a multicentre, single-arm, phase 2 trial. Lancet
Oncol. 25:1453–1464. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang C, Chen KN, Chen Q, Wu L, Wang Q, Li
X, Ying K, Wang W, Zhao J, Liu L, et al: Neoadjuvant nivolumab plus
chemotherapy versus chemotherapy for resectable NSCLC:
Subpopulation analysis of Chinese patients in CheckMate 816. ESMO
Open. 8:1020402023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Ma X, Ma K, Chen X, He H, Zhao X,
Fan M and Xu Y: Efficacy and safety of neoadjuvant
chemoimmunotherapy and chemotherapy in patients with potentially
resectable stage IIIA/IIIB NSCLC: A retrospective study. Front
Immunol. 15:14792632025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu
L, Zhang P, Zhao G, Yang F, Han G, et al: Perioperative
tislelizumab plus neoadjuvant chemotherapy for patients with
resectable non-small-cell lung cancer (RATIONALE-315): An interim
analysis of a randomised clinical trial. Lancet Respir Med.
13:119–129. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heymach JV, Harpole D, Mitsudomi T, Taube
JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, et
al: Perioperative durvalumab for resectable non-small-cell lung
cancer. N Engl J Med. 389:1672–1684. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weder W, Collaud S, Eberhardt WEE,
Hillinger S, Welter S, Stahel R and Stamatis G: Pneumonectomy is a
valuable treatment option after neoadjuvant therapy for stage III
non-small-cell lung cancer. J Thorac Cardiovasc Surg.
139:1424–1430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
White A, Kucukak S, Bueno R, Servais E,
Lee DN, Colson Y, Jaklitsch M, McNamee C, Mentzer S, Wee J and
Swanson SJ: Pneumonectomy is safe and effective for non-small cell
lung cancer following induction therapy. J Thorac Dis. 9:4447–4453.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang G, Liu L, Zhang J and Li S: The
analysis of prognosis factor in patients with non-small cell lung
cancer receiving pneumonectomy. J Thorac Dis. 12:1366–1373. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schirren J, Bölükbas S, Bergmann T,
Fisseler-Eckhoff A, Trainer S and Beqiri S: Prospective study on
perioperative risks and functional results in bronchial and
bronchovascular sleeve resections. Thorac Cardiovasc Surg.
57:35–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maurizi G, D'Andrilli A, Venuta F and
Rendina EA: Bronchial and arterial sleeve resection for
centrally-located lung cancers. J Thorac Dis. 8 (Suppl
11):S872–S881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nitsche LJ, Jordan S, Demmy T, Dexter E,
Hennon M, Nwogu C, Yendamuri S and Picone A: Analyzing the impact
of minimally invasive surgical approaches on post-operative
outcomes of pneumonectomy and sleeve lobectomy patients. J Thorac
Dis. 15:2497–2504. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kates M, Swanson S and Wisnivesky JP:
Survival following lobectomy and limited resection for the
treatment of stage I non-small cell lung cancer<=1 cm in size: A
review of SEER data. Chest. 139:491–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi Y, Wu S, Ma S, Lyu Y, Xu H, Deng L and
Chen X: Comparison between wedge resection and
lobectomy/segmentectomy for early-stage non-small cell lung cancer:
A bayesian meta-analysis and systematic review. Ann Surg Oncol.
29:1868–1879. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parascandola M and Xiao L: Tobacco and the
lung cancer epidemic in China. Transl Lung Cancer Res. 8 (Suppl
1):S21–S30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu Y, Ren SY, Wang RY, Zeng C, Li JN, Xiao
P, Wu F, Yu FL and Liu WL: Surgical outcomes after neoadjuvant
chemoimmunotherapy for resectable non-small cell lung cancer. Front
Oncol. 11:6840702021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Romero Román A, Campo-Cañaveral de la Cruz
JL, Macía I, Escobar Campuzano I, Figueroa Almánzar S, Delgado Roel
M, Gálvez Muñoz C, García Fontán EM, Muguruza Trueba I, Romero
Vielva L, et al: Outcomes of surgical resection after neoadjuvant
chemoimmunotherapy in locally advanced stage IIIA non-small-cell
lung cancer. Eur J Cardiothorac Surg. 60:81–88. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gu L, Wang X, Sun Y, Xu Y, Niu X, Zhao R,
Yao Y, Jian H, Han Y, Wei J, et al: An open, observational,
three-arm clinical study of 2–3 cycles of treatment as neoadjuvant
therapy in operable locally advanced non-small cell lung cancer: An
interim analysis. Front Immunol. 13:9382692022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian
F, Liu H, Gu Z, Huang L, Lu Q, et al: Neoadjuvant camrelizumab plus
platinum-based chemotherapy vs chemotherapy alone for chinese
patients with resectable stage IIIA or IIIB (T3N2) non-small cell
lung cancer: The TD-FOREKNOW randomized clinical trial. JAMA Oncol.
9:1348–1355. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heymach JV, Mitsudomi T, Harpole D,
Aperghis M, Jones S, Mann H, Fouad TM and Reck M: Design and
rationale for a phase III, double-blind, placebo-controlled study
of neoadjuvant durvalumab + chemotherapy followed by adjuvant
durvalumab for the treatment of patients with resectable stages II
and III non-small-cell lung cancer: The AEGEAN trial. Clin Lung
Cancer. 23:e247–e251. 2022. View Article : Google Scholar : PubMed/NCBI
|
